Verve Therapeutics

Yahoo Finance • 19 days ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to... Full story

Yahoo Finance • 24 days ago

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive of... Full story

Yahoo Finance • 5 months ago

Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5?

We recently compiled a list of 7 Best NASDAQ Stocks Under $5. In this article, we will look at where Verve Therapeutics, Inc. (NASDAQ:VERV) ranks among the best NASDAQ stocks under $5. Job Market Cools Yet Economists Remain Optimistic Abo... Full story

Yahoo Finance • 5 months ago

Jim Cramer on Verve Therapeutics Inc. (VERV): ‘I Think It’s A Winner’

We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks.In this article, we are going to take a look at where Verve Therapeutics Inc. (NASDAQ:VERV) stands against Jim Cramer's other must-watch stocks. In a recent episode... Full story

Yahoo Finance • last year

2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals. But CRISPR isn't the only biot... Full story

Yahoo Finance • last year

12 Best Genomics Stocks To Buy Now

In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there's one t... Full story

Yahoo Finance • last year

Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today an... Full story

Yahoo Finance • last year

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today an... Full story

Yahoo Finance • last year

Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 20, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) inve... Full story

Yahoo Finance • last year

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0... Full story

Yahoo Finance • last year

Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Collaboration with Eli Lilly and Company (Lilly) Expands Through Lilly’s... Full story

Yahoo Finance • last year

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the lif... Full story

Yahoo Finance • last year

Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that the com... Full story

Yahoo Finance • last year

Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar K... Full story

Yahoo Finance • last year

Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointm... Full story

Yahoo Finance • 2 years ago

Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease

Verve to Receive $60 Million in Combined Upfront Payment and Equity Investment; Additional Capital Positioned to Extend Verve’s Expected Cash Runway into 2026 Verve has Opt-in Rights to Co-fund and Share in Potential Margins of Products R... Full story

Yahoo Finance • 2 years ago

12 Best Short Squeeze Stocks to Buy Now

In this article we present the list of 12 Best Short Squeeze Stocks to Buy Now. Click to skip ahead and see the 5 Best Short Squeeze Stocks to Buy Now. Plug Power, Inc. (NASDAQ:PLUG), Cinemark Holdings, Inc. (NYSE:CNK), and Allogene Thera... Full story

Yahoo Finance • 2 years ago

Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results

heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical Trial Initiation Expected in the First Ha... Full story

Yahoo Finance • 2 years ago

Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kat... Full story

Yahoo Finance • 2 years ago

Top 10 CRISPR Stocks To Buy

In this article, we discuss the top 10 CRISPR stocks to buy. If you want to see more stocks in this selection, check out Top 5 CRISPR Stocks To Buy. Molecular biology, genetics, and genomics are in a significant period in history where te... Full story